19 EGFR mutation rate in TRANSCRIPT: A study to assess the incidence of EGFR mutations in UK NSCLC patients with newly diagnosed locally advanced or metastatic disease. A single arm, open label studyInternationa
EGFR mutations were detected in 196 of 382 NSCLCs (51.3%) and were more frequent in women than in men (65.7% versus 34.3%, p < 0.001) and in nonsmokers than in smokers (63.4% versus 32.0%, p < 0.001). Regarding histologic subtypes of adenocarcinoma, mixed acinar and BAC pattern showe...
Mutations in KRAS, PIK3CA and PTEN genes have recently emerged as the potential predictive factors of low/ absent response to EGFR-targeted therapy. Given that cur- rently there is a lack of data on gene mutations associated with EGFR, a potential target for PSCCE, except a few case reports...
BC occurrence is widely believed to be influenced by both genetics (such as mutations in BRCA) [4,5] and risk factors in the environment [6,7,8]. Therefore, researchers are trying to come up with better prevention strategies for women by adjusting the exposure of BC factors [9,10]. ...
High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012; 7: 323-330.Sun PL, Seol H, Lee H J, et al. High i...
Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) histology (NSCLC/ADC). Robust data exist regarding the prevalence of EGFR mutations in Western and Asian patients with NSCLC/...
Although EGFR mutations were most frequent in patients with ADC and never/light smokers from Asia, and KRAS mutations were most frequent in patients with ADC and ever/heavy smokers from Western countries, both were detected outside these subgroups.Potential molecular pathology segments of NSCLC were...
Objectives: Advanced non-small cell lung cancer (NSCLC) patients harboring non-resistant uncommon epidermal growth factor receptor (EGFR) mutations have stepped into the era of targeted therapy. This study aimed to investigate the incidence of acquired T790M mutation and their outcome to subsequent ...
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have become the cornerstone in the treatment of lung cancers that harbor EGFR mutations, but also play an important role in the treatment of other lung cancers and have been investigated among various types of solid tumors. How...
From March 2017 reflex testing for PD-L1 was performed in all newly diagnosed as well as recurrent NSCLC patients, with registration of the precise proportion of PD-L1 expression when feasible. Histological tests for driver mutations of epidermal growth factor receptor (EGFR) and anaplastic lymphoma...